What is the appropriate workup for newly identified neutropenia?

Workup for Newly Identified Neutropenia

For newly identified neutropenia, immediately repeat the complete blood count (CBC) with differential to confirm the finding, then proceed with a systematic evaluation based on severity, clinical presentation, and infection history to distinguish between acquired and congenital causes.

Initial Confirmation and Classification

Start by confirming the diagnosis with a repeat CBC with differential, as transient neutropenia from viral illnesses is common 1. Neutropenia is defined as an absolute neutrophil count (ANC) <1,500/μL in adults and children >1 year, or <1,000/μL in infants 2.

Classify severity immediately:

• Mild: 1,000-1,500/μL
• Moderate: 500-999/μL
• Severe: <500/μL 2

This classification drives urgency and infection risk assessment.

Critical Initial Assessment

Evaluate for febrile neutropenia first - this is an oncologic emergency requiring immediate action. If temperature ≥101°F (single reading) or ≥100.4°F sustained for 1 hour with ANC <500/μL, this warrants emergent evaluation and empiric broad-spectrum antibiotics 2.

Assess infection history and severity:

• Frequency and severity of past infections
• Current signs of infection (fever, oral ulcers, skin infections, pneumonia)
• Need for hospitalization for infections
• Response to previous treatments 3, 4

Laboratory Workup Algorithm

First-Tier Testing (All Patients):

• Serial CBCs with differential - obtain 2-3 times weekly for 6 weeks to identify cyclic patterns (cyclic neutropenia has 21-day cycles) 4, 5
• Peripheral blood smear - evaluate for dysplasia, abnormal cells, or other cytopenias 4
• Comprehensive metabolic panel - assess liver/kidney function
• Vitamin B12, folate, and copper levels - nutritional deficiencies are reversible causes 2
• Antinuclear antibody (ANA) - screen for autoimmune disorders 4

Second-Tier Testing (Based on Initial Results):

If isolated neutropenia without other cytopenias:

• Antineutrophil antibodies (only interpret in context of clinical findings and bone marrow results, as sensitivity/specificity is limited) 5
• HIV, hepatitis B/C serology - infection-related causes 4
• Immunoglobulin levels 4

If concerning features present (severe neutropenia, recurrent infections, poor response to treatment, family history):

• Bone marrow aspiration and biopsy with cytogenetics - essential to evaluate cellularity, maturation arrest, dysplasia, and exclude malignancy 3, 5
• Genetic testing - particularly if congenital neutropenia suspected (young age, family history, dysmorphic features, associated anomalies) 2, 1

Distinguishing Acquired vs. Congenital Causes

Acquired Neutropenia Features:

• Adult onset
• Medication exposure (review ALL medications for idiosyncratic drug reactions)
• Recent viral infection
• Autoimmune disease history
• Chemotherapy exposure
• No family history 2, 1

Congenital Neutropenia Red Flags:

• Onset in childhood/infancy
• Family history of neutropenia or early deaths from infection
• Cyclic pattern (every 21 days)
• Associated congenital anomalies
• Failure to thrive
• Recurrent severe infections from early life 2, 5

Common Pitfalls to Avoid

Do not assume benign ethnic neutropenia without proper evaluation. While individuals of African, Middle Eastern, or West Indian descent may have lower baseline ANC (1,000-1,500/μL), this remains a diagnosis of exclusion requiring confirmation that the patient is asymptomatic with no infection history 4.

Do not order neutrophil antibody testing in isolation - results are difficult to interpret and should only be used alongside bone marrow findings and clinical context 5.

Do not delay bone marrow examination in severe chronic neutropenia - this is essential for risk stratification and excluding pre-leukemic conditions, particularly in congenital forms that carry MDS/AML risk 6, 5.

When to Refer to Hematology

Immediate referral:

• ANC <500/μL with recurrent or severe infections
• Any suspicion of congenital neutropenia
• Bone marrow findings showing dysplasia or cytogenetic abnormalities
• Poor response to initial management
• Need for G-CSF therapy consideration 3

The European guidelines emphasize combining clinical findings with classical laboratory testing and advanced mutational analyses for proper characterization and risk stratification across the entire spectrum of neutropenia patients 3.